Develop comparative drug profiles Support drug development Provide feedback on database

Osteoarthritis pain Paclitaxel for MBC Inflammable bowel disease Lower back pain

Key features Exclusive data model Unique and continuously improving database
structure that reflects therapeutic area-specific knowledge and accumulative experience in modelbased meta-analysis

Flexible Scope Readily expandable to include additional drug

classes, indications, and endpoints

Customizable with internal proprietary data

(CSR, patient-level data, etc)

Absolute Decrease in LDL

Absolute Decrease in Triglycerides

Unbiased, High Quality Data Multiple sources of information including PubMed,

clinicaltrials.gov, meeting abstracts, and regulatory reviews

Rigorous quality process including graphical

exploration and final QC by experienced MBMA modelers

Absolute Increase in HDL

Data is augmented to be model-friendly (e.g.,

missing covariates imputed, endpoint units normalized, background treatment categorized, etc)

Jaap Mandema, Kevin Sweeney, Steven Terra, Vaishali Sahasrabudhe. Model-based meta-analysis of the hba1c lowering effect of pf-04971729, a sodium glucose co-transporter-2 inhibitor (sglt2i), in Comparison to other sglt2iand anti-diabetic agents (ada)
(http://www.quantitativesolutions.net/pdf/HbA1cMBMA-ADA2012-final.pdf)

Dose (mg/day)

Jaap Mandema, Kevin Sweeney, Steven Terra, Vaishali Sahasrabudhe Model-based meta-analysis of the effect on body weight of pf-04971729, a sodium glucose co-transporter-2 inhibitor (sglt2i), in Comparison to other sglt2iand anti-diabetic agents (ada) (http://www.quantitativesolutions.net/pdf/BW-MBMA-ADA2012-final.pdf)